keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis arthritis

keyword
https://www.readbyqxmd.com/read/28805045/safety-and-efficacy-of-intravenous-golimumab-in-patients-with-active-psoriatic-arthritis-results-through-week-24-of-the-go-vibrant-study
#1
Arthur Kavanaugh, M Elaine Husni, Diane D Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H Leu, Elizabeth C Hsia
OBJECTIVE: Evaluate the safety and efficacy of intravenous golimumab in psoriatic arthritis (PsA). METHODS: In this Phase 3, randomized, double-blind, placebo-controlled trial, patients were randomized to intravenous placebo (n=239) or golimumab 2 mg/kg (n=241) at weeks 0, 4, 12, and 20. The primary endpoint was the proportion of patients with ≥20% improvement in ACR criteria (ACR20) at week14. Controlled secondary endpoints included change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI), proportions of patients with ACR50, ACR70, and ≥75% improvement in Psoriasis Area and Severity Index (PASI75) at week14, and change from baseline in total PsA-modified van der Heijde-Sharp (vdH-S) score at week24...
August 13, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28804988/patterns-of-systemic-treatment-for-psoriatic-arthritis-in-the-united-states-2004-2015
#2
Moa P Lee, Joyce Lii, Yinzhu Jin, Rishi J Desai, Daniel H Solomon, Joseph F Merola, Seoyoung C Kim
OBJECTIVE: To examine trends in use of systemic disease-modifying antirheumatic drugs (DMARD) among patients with psoriatic arthritis (PsA) in the U.S. METHODS: Using claims data (2004-2015) from a large U.S. commercial healthplan, we identified patients with PsA who initiated DMARDs. We examined baseline patient characteristics and initial treatment patterns. We then assessed changes in the DMARD regimen over the 12-month period after the 1(st) DMARD initiation date...
August 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28803431/sb2-an-infliximab-biosimilar
#3
Yvette N Lamb, Lesley J Scott, Emma D Deeks
SB2 is a biosimilar of the reference anti-TNF-α antibody infliximab. In May 2015, it was approved in the EU for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis. It is also approved in these indications in several other countries, including Korea, the USA and Australia. Characterization of SB2 in preclinical studies showed that it is similar to reference infliximab...
August 12, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28801811/association-of-variably-expressed-kir3dl1-alleles-with-psoriatic-disease
#4
Jeffrey Berinstein, Remy Pollock, Fawnda Pellett, Arane Thavaneswaran, Vinod Chandran, Dafna D Gladman
The purpose of this study is to examine the genetic interaction of variably expressed killer cell immunoglobulin-like receptor (KIR) 3DL1 alleles with their cognate ligand, human leukocyte antigen (HLA)-Bw4, in susceptibility to psoriatic disease (PsD). A novel allelic typing system was developed to differentiate KIR3DL1 alleles (*High, *Low, *Null expression, and 3DS1), in PsD patients, including those with psoriatic arthritis (PsA) and cutaneous psoriasis without arthritis (PsC) and healthy controls. Frequencies of each KIR3DL1 allele, Bw4-80I and Bw4-80T, as well as the genetic interaction between the KIR3DL1 alleles and the Bw4 epitope were analyzed...
August 11, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28799796/immune-modulation-by-curcumin-the-role-of-interleukin-10
#5
Hamid Mollazadeh, Arrigo F G Cicero, Christopher N Blesso, Matteo Pirro, Muhammed Majeed, Amirhossein Sahebkar
Cytokines are small secreted proteins released by different types of cells with specific effects on cellular signaling and communication via binding to their receptors on the cell surface. IL-10 is known to be a pleiotropic and potent anti-inflammatory and immunosuppressive cytokine that is produced by both innate and adaptive immunity cells including dendritic cells, macrophages, mast cells, natural killer cells, eosinophils, neutrophils, B cells, CD8(+) T cells, and TH1, TH2, and TH17 and regulatory T cells...
August 11, 2017: Critical Reviews in Food Science and Nutrition
https://www.readbyqxmd.com/read/28796405/rate-of-serious-infection-in-patients-who-are-prescribed-systemic-biologic-or-nonbiologic-agents-for-psoriasis-a-large-single-center-retrospective-observational-cohort-study
#6
Chantelle Carneiro, Romi Bloom, Erin Ibler, Sara Majewski, Kimberly A Sable, Nicholas J Guido, Jennifer Day, Salvatore Nocadello, Aleksandra G Florek, Dennis P West, Beatrice Nardone
BACKGROUND: Systemic biologic and nonbiologic agents used to treat psoriasis may or may not contribute to serious infection (SI) risk. Safety data, particularly for biologic agents, and associated risk for SI, are scarce. The study's aim was to explore the risk for SI in psoriasis patients exposed to systemic biologic or nonbiologic agents. METHODS: A large, single-center electronic medical record repository was searched between January 2010 and December 2014. Records for patients prescribed a systemic agent for psoriasis (SAP) with psoriasis or psoriatic arthritis diagnoses were included (ICD-9 codes 696...
August 10, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28790811/retrospective-analysis-to-describe-associations-between-tumor-necrosis-factor-alpha-inhibitors-and-copd-related-hospitalizations
#7
Neil A Accortt, James B Chung, Machaon Bonafede, Brendan L Limone, David M Mannino
BACKGROUND: Limited information exists on the impact of tumor necrosis factor inhibition on COPD exacerbations. This retrospective study characterized this impact among COPD patients with underlying autoimmune conditions, exposed to tumor necrosis factor inhibitors (TNFi) and/or non-biologic disease-modifying antirheumatic drugs (DMARDs). PATIENTS AND METHODS: Adult COPD patients with ≥1 diagnosis for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) before or within 6 months following the index COPD diagnosis were identified from the Truven Health MarketScan(®) databases...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28790368/signs-of-innate-immune-activation-and-premature-immunosenescence-in-psoriasis-patients
#8
Liisi Šahmatova, Elena Sügis, Marina Šunina, Helen Hermann, Ele Prans, Maire Pihlap, Kristi Abram, Ana Rebane, Hedi Peterson, Pärt Peterson, Külli Kingo, Kai Kisand
Psoriasis is a chronic inflammatory disease that affects skin and is associated with systemic inflammation and many serious comorbidities ranging from metabolic syndrome to cancer. Important discoveries about psoriasis pathogenesis have enabled the development of effective biological treatments blocking the T helper 17 pathway. However, it has not been settled whether psoriasis is a T cell-mediated autoimmune disease or an autoinflammatory disorder that is driven by exaggerated innate immune signalling. Our comparative gene expression and hierarchical cluster analysis reveal important gene circuits involving innate receptors...
August 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28777869/-progress-in-genetic-research-on-psoriatic-arthritis
#9
Yan Ju, Erle Dang, Chunxiang Yang, Hongping Song
Psoriatic arthritis is a form of inflammatory arthritis found among patients with psoriasis, which can lead to pain, swelling or stiffness in one or more joints and even movement disorders. Epidemiological studies have shown a higher heritability for psoriatic arthritis compared with psoriasis vulgaris. With the evolvement of DNA sequencing, many genes have been associated with psoriasis vulgaris and psoriatic arthritis, which included MHC, TNF, LCE, IL23R, IL12B, TRAF3IP2 and TNFAIP3, though some, such as MHC, IL-13 and PTPN22, have been specifically associated with psoriatic arthritis...
August 10, 2017: Zhonghua Yi Xue Yi Chuan Xue za Zhi, Zhonghua Yixue Yichuanxue Zazhi, Chinese Journal of Medical Genetics
https://www.readbyqxmd.com/read/28777803/gm-csf-in-murine-psoriasiform-dermatitis-redundant-and-pathogenic-roles-uncovered-by-antibody-induced-neutralization-and-genetic-deficiency
#10
Tatjana Scholz, Andreas Weigert, Bernhard Brüne, Christian D Sadik, Beate Böhm, Harald Burkhardt
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic, Th17-derived cytokine thought to critically contribute to the pathogenesis of diverse autoimmune diseases, including rheumatoid arthritis and psoriasis. Treatment with monoclonal antibodies that block GM-CSF activity is associated with favorable therapeutic effects in patients with rheumatoid arthritis. We evaluated the role of GM-CSF as a potential target for therapeutic interference in psoriasis using a combined pharmacologic and genetic approach and the mouse model of imiquimod-induced psoriasiform dermatitis (IMQPD)...
2017: PloS One
https://www.readbyqxmd.com/read/28777015/is-weekly-dose-of-adalimumab-a-simple-approach-for-resistant-psoriasis
#11
Sara Mazzilli, Arianna Zangrilli, Mauro Bavetta, Luca Bianchi
Backgroud: In real life, dose escalation can be a good approach for increasing efficacy in a subgroup of patients with an insufficient response to biologic therapy, reducing the signs and symptoms of psoriasis and improving the quality of life (QOL). OBJECTIVE: To determine the effectiveness of escalating adalimumab dosage from 40 mg eow to 40 mg weekly in a patient affected by psoriasis (PsO) and psoriatic arthritis (PsA) with < PASI 50 response following 364 weeks treatment...
August 4, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28776364/jaccoud-s-arthropathy-an-unusual-manifestation-of-idiopathic-retroperitoneal-fibrosis-rapid-improvement-of-symptoms-after-tocilizumab-treatment
#12
M Benucci, A Damiani, F Li Gobbi, V Grossi, M Infantino, A Arena, M Manfredi
Jaccoud's arthropathy (JA) is a chronic, non erosive, rheumatoid-like deformity associated with rheumatic fever (RF) and systemic lupus erythematosus and with other diseases such as psoriatic arthritis, connective tissue diseases, hypocomplementemic urticarial vasculitis, infections, sarcoidosis and neoplasia. We described a case of JA in a patient with cutaneous psoriasis but with a particular disease evolution associated with idiopathic retropritoneal fibrosis (IRF), evaluated with computed tomography, magnetic resonance and 18F-FDG PET/ CT...
August 3, 2017: Reumatismo
https://www.readbyqxmd.com/read/28771892/therapeutic-depletion-of-myeloid-lineage-leukocytes-by-adsorptive-apheresis-for-psoriatic-arthritis-efficacy-of-a-non-drug-intervention-for-patients-refractory-to-pharmacologics
#13
Takuro Kanekura, Mariko Seishima, Masaru Honma, Takafumi Etou, Hikaru Eto, Keiko Okuma, Yukari Okubo, Yukie Yamaguchi, Takeshi Kambara, Tomotaka Mabuchi, Yasushi Suga, Akimichi Morita, Kiyofumi Yamanishi, Daisuke Tsuruta, Kei Itoh, Ken Yamaji, Shigaku Ikeda
Psoriatic arthritis (PsA), a chronic inflammatory arthropathy associated with psoriasis, is an intractable immune disorder and refractory to pharmacological intervention. We assessed efficacy of selective depletion of myeloid lineage leukocytes in patients with PsA in a multicenter setting. A total of 20 patients with moderate to severe PsA refractory to conventional and biological disease-modifying antirheumatic drugs were included. Eligible patients had 3 points or more in the classification criteria for PsA...
August 3, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28771778/new-onset-or-transition-of-disease-state-of-psoriatic-arthritis-during-treatment-with-ustekinumab-a-single-center-retrospective-study
#14
Akihiko Asahina, Yoshinori Umezawa, Mami Momose, Hiromi Honda, Koichi Yanaba, Hidemi Nakagawa
Ustekinumab (UST) is a treatment option for psoriatic arthritis (PsA), but recent observations indicate that some psoriatic patients may experience new onset of PsA or worsening of pre-existent PsA. We retrospectively analyzed all cases of psoriasis vulgaris (PsV) and PsA treated with UST in our facility between 2011 and 2015. PsA developed in eight out of 179 PsV patients, mostly later than 8 months after initiation of UST. It was generally not severe, and none had received tumor necrosis factor (TNF)-α inhibitors previously, indicating that the possibility of unmasking pre-existing subclinical arthritis is minimal...
August 3, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28769136/nail-involvement-in-psoriatic-arthritis
#15
REVIEW
Piotr Sobolewski, Irena Walecka, Klaudia Dopytalska
Nail psoriasis is considered a significant psychological and social problem causing functional impairment in affected patients. Nail changes hamper their daily and occupational activities and contribute to a worse quality of life. Almost 50% of patients with psoriasis vulgaris and up to 80% of patients with psoriatic arthritis are afflicted with nail lesions. The important correlation between psoriatic arthritis and nail changes is well established - the presence of the latter is a strong predictor of the development of arthritis...
2017: Reumatologia
https://www.readbyqxmd.com/read/28765121/novel-therapies-for-immune-mediated-inflammatory-diseases-what-can-we-learn-from-their-use-in-rheumatoid-arthritis-spondyloarthritis-systemic-lupus-erythematosus-psoriasis-crohn-s-disease-and-ulcerative-colitis
#16
REVIEW
Kenneth F Baker, John D Isaacs
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge. As well as providing superior treatments for immune-mediated inflammatory diseases (IMIDs), such therapies also offer unrivalled opportunities to study the underlying immunopathological basis of these conditions.In this review, we explore recent approaches to the treatment of IMIDs and the insights to pathobiology that they provide...
August 1, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28762213/comparative-effectiveness-of-adalimumab-versus-secukinumab-for-the-treatment-of-psoriatic-arthritis-a-matching-adjusted-indirect-comparison
#17
Vibeke Strand, Keith A Betts, Manish Mittal, Jinlin Song, Martha Skup, Avani Joshi
INTRODUCTION: The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for the treatment of active PsA. METHODS: A matching-adjusted indirect comparison was conducted using individual patient data from the ADEPT trial of adalimumab and published data from FUTURE I and II...
July 31, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28761301/a-case-of-nail-psoriasis-improved-by-treatment-with-golimumab-in-a-psoriatic-arthritis-patient
#18
So Young Jung
No abstract text is available yet for this article.
August 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28758274/pregnancy-and-infant-outcomes-including-major-congenital-malformations-among-women-with-chronic-inflammatory-arthritis-or-psoriasis-with-and-without-etanercept-use
#19
Wendy J Carman, Neil A Accortt, Mary S Anthony, Janet Iles, Cheryl Enger
PURPOSE: Objectives were to quantify prevalence estimates of pregnancy and infant outcomes including major congenital malformations (MCMs) by etanercept (ETN) exposure among infants born to women with chronic inflammatory arthritis (cIA) or psoriasis (PsO). METHODS: Claims-based data delineated pregnancy exposures and outcomes of live or nonlive births among women with cIA and PsO (ETN exposed, unexposed) and general population (GP) comparators. Infant outcomes were determined for live-born infants covered by the mother's insurer...
July 31, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28752980/-ultrasonic-features-of-enthesitis-a-comparison-between-patients-with-psoriasis-vulgaris-and-patients-with-psoriatic-arthritis
#20
Yuan-Jiao Tang, Xi Xiang, Yu-Jia Yang, Li-Yun Wang, Ying He, Li Qiu
OBJECTIVE: To compare the ultrasonic features of enthesitis between psoriatic arthritis and psoriasis vulgaris. METHODS: A total of 39 patients with psoriatic arthritis (PsA group), 60 with psoriasis vulgaris (non-PsA group) and 60 healthy people (control group) participated in this study. They were examined by two-dimensional and color Doppler ultrasound on the entheses of bilateral femoral quadriceps tendons, patella tendons, Achilles tendons, plantar fasciae, common flexor tendons and common extensor tendons...
July 2017: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
keyword
keyword
56034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"